首页> 外文OA文献 >Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

【2h】

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

机译：HSP90抑制剂Auy922和Erlotinib对EGFR-突变体肺癌的相I / II研究，具有对表皮生长因子受体酪氨酸激酶抑制剂的获得性抗性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Melissa L. Johnson; Helena A. Yu; Eric M. Hart; Bing Bing Weitner; Alfred W. Rademaker; Jyoti D. Patel; Mark G. Kris; Gregory J. Riely;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Johnson Melissa L., Yu Helena A., Hart Eric M., Journal of Clinical Oncology . 2015,第15期

机译：HSP90抑制剂AUY922和Erlotinib用于对表皮生长因子受体酪氨酸激酶抑制剂具有耐药性的EGFR突变型肺癌的I / II期研究
2. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [J] . Johnson Melissa L., Yu Helena A., Hart Eric M., Journal of Clinical Oncology . 2015,第15期

机译：HSP90抑制剂Auy922和Erlotinib对EGFR-突变体肺癌的相I / II研究，具有对表皮生长因子受体酪氨酸激酶抑制剂的获得性抗性
3. Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor ( EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303) [J] . Karen L. Reckamp, Paul H. Frankel, Nora Ruel, Frontiers in Oncology . 2019,第2016期

机译：卡巴替尼+厄洛替尼在晚期表皮生长因子受体（ EGFR ）-突变型非小细胞肺癌中进展性疾病的表皮生长因子受体酪氨酸激酶抑制剂治疗的II期临床试验：加利福尼亚癌症协会II期试验（NCI 9303）
4. QSAR Study of Quinazoline Derivatives as Inhibitor of Epidermal Growth Factor Receptor-Tyrosine Kinase (EGFR-TK) [C] . La Ode Aman, Widisusanti Abdulkadir, Julitha Geybie Rembet, International Conference on Computation for Science and Technology . 2015

机译：喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶（EGFR-TK）抑制剂的QSAR研究
5. Unanticipated Effects of Tyrosine Kinase Inhibitors on Vitamin D Receptor Expression and Gene Regulation In Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer. [D] . Timberlake, Alexandra F. 2017

机译：酪氨酸激酶抑制剂对表皮生长因子受体突变的非小细胞肺癌中维生素D受体表达和基因调控的意外影响。
6. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Melissa L. Johnson, Helena A. Yu, Eric M. Hart, -1

机译：HSP90抑制剂AUY922和Erlotinib用于对表皮生长因子受体酪氨酸激酶抑制剂具有耐药性的EGFR突变型肺癌的I / II期研究
7. >Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors [O] . Wen Gao, Jing He, Shi-Dai Jin, 2019

机译：>初始表皮生长因子受体酪氨酸激酶抑制剂治疗和EGFR外显子抑制剂的抗血液抗性抗血液肺癌患者T790M突变抗性抗性后，抗抗血疱剂患者的抗性，抗抗血管生长因子受体酪氨酸激酶抑制剂

Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

著录项

引文网络

相似文献

相关主题

期刊订阅